California accepts 'tech-check-tech' in hospitals
June 5th 2006Pharmacists in California have finally agreed to technicians checking technicians in hospital settings. Buoyed by studies showing that putting hospital pharmacists on the floor can reduce medication errors and patient deaths, the state board of pharmacy has voted to let techs check medication cassette fills by other technicians.
Consumer protection under Part D
June 5th 2006Mark McClellan, M.D., Ph.D., administrator of CMS, has pledged that the government will be on guard for fraud or practices that mislead seniors covered under prescription drug plans (PDPs). To that end, Medicare has about 500 staff members nationwide to investigate fraud allegations and $80 million available to track and enforce adherence to Medicare policies.
New ways to manage diabetic neuropathy
June 5th 2006Statistics show that at least one-half of all people with diabeteshave diabetic peripheral neuropathy (DPN). And while many of thesepatients may develop a lack of sensation, approximately 11% havechronic and painful symptoms that seriously affect their quality oflife. For this reason, and the current lack of consensus about thecondition's pathophysiology and most effective treatment, a groupof 11 pain specialists convened in a two-day conference in 2005 tocreate the first diabetic peripheral neuropathic pain (DPNP)guidelines.
Monthly injection new in the fight for sobriety
June 5th 2006For a condition where compliance can be a big issue, a newonce-monthly injection will soon be available to help alcoholicskick the habit. In April, the Food & Drug Administrationapproved Vivitrol (naltrexone for extended-release injectablesuspension), a new treatment option from Alkermes and Cephalon.Vivitrol is indicated for alcohol-dependent patients who are ableto abstain from drinking in an outpatient setting and are notactively drinking at the beginning of treatment.
Compounding supplier recalls tacrolimus
May 30th 2006Bulk Rx ingredient supplier Spectrum Laboratory has recalled alllots of tacrolimus powder due to sub-potency in some lots. Allpharmacies that have received Spectrum's tacrolimus powder shouldstop using it immediately and contact the company to makearrangements to return it.
Migraine drug to be available OTC in England
May 30th 2006The Medicines and Healthcare Products Regulatory Agency, London,has announced that the migraine medication sumatriptan (Imigran) isto be reclassified from Prescription Only Medicine (POM) toPharmacy Medicine (P) status, making it available from pharmacieswithout the need for a prescription. With England setting aprecedent, will the United States be next?
Contact lens solution permanently yanked
May 30th 2006Bausch & Lomb has decided to permanently remove from marketsworldwide its ReNu with MoistureLoc contact lens cleaning solution,based on data suggesting that the product may increasesusceptibility to Fusarium. The company has proposed theformulation as the potential root cause of the increased relativerisk of Fusarium keratitis.
NIH weighs efficacy of multivitamins, minerals
May 30th 2006An independent panel convened by the NIH Office of MedicalApplications of Research and the Office of Dietary Supplements hasassessed the available evidence of multivitamin/minerals (MVMs) andmade recommendations regarding certain supplements. The panel'srecommendations include the following: the combined use of calciumand vitamin D protects the bone health of postmenopausal women;antioxidants and zinc help nonsmoking adults with early-stage,age-related macular degeneration; and women of childbearing ageshould take folate daily.
Drug abuse awareness campaign launched
May 30th 2006The Consumer Healthcare Products Association has joined forces withthe Partnership for a Drug-Free America to launch an advertisingcampaign designed to curb the abuse of prescription and OTCmedicines and to draw public attention to the substance abuse trendamong teenagers. At dual press conferences held recently inWashington, D.C., and New York, TV, print, and radio public serviceads were unveiled.
Medco reaches tentative settlement
May 30th 2006Medco Health Solutions reached a tentative agreement to pay $163million to settle federal fraud charges stemming from twowhistle-blower suits filed by pharmacists against the giant PBM.Still slated for trial in June, the Medco complaint was filed inDecember 2003 by U.S.
CMS holds off on Medicaid price data
May 30th 2006CMS will not publicly release current average manufacturer prices(AMP) slated to be used to calculate Medicaid reimbursement ongenerics, according to administrator Mark McClellan. With inputfrom pharmacy, the agency has concluded that the definition of AMPmust be revised to reflect the prices retail pharmacies actuallypay for generics.
Part D plans must use standard Rx claim codes
May 30th 2006Beginning July 1, all Medicare Part D drug plans must use approvedstandardized reject codes developed by groups representingpharmacy, PBMs, and insurers. The change from best practice tomandate was announced by CMS administrator Mark McClellan, who saidit is fundamentally important to reduce administrative burdens onpharmacists.
More insulin syringes recalled
May 30th 2006Boca Medical Products and the FDA have notified consumers andhealthcare professionals of an extension of an earlier recall ofUltilet insulin syringes and the additional recall of Closercareinsulin syringes because of bacterial contamination withPaenibacillus. This presents a risk of local infection due to softtissue injection with a contaminated syringe as well as a risk ofintroduction of contaminating organisms into a previously sterilevial.
Approval granted for new Focalin XR labeling
May 30th 2006Results of two studies in patients aged six to 12 years have ledNovartis to update the labeling of dexmethylphenidate HCl (FocalinXR) extended-release capsules. Significant improvements in ADHDsymptoms were observed at every hour up to 12 hours afteradministration of 20 mg of the drug compared with placebo.
Name confusion leads to awareness campaign
May 30th 2006AstraZeneca has launched a campaign directed at healthcareproviders after receiving reports of confusion between brand-namedrugs Toprol-XL (metoprolol succinate), Topamax (topiramate,Ortho-McNeil), and Tegretol (carbamazepine, Novartis) and TegretolXR that have led to medication errors. The effort will aim toincrease awareness of the problem and reinforce accurateprescribing and dispensing of Toprol-XL.
Temporary change in MCV4 recommendations
May 30th 2006Sanofi-Pasteur, manufacturer of the meningococcalpolysaccharide-protein conjugate vaccine (MCV4), has announced ashortage of the vaccine that will last at least through the summerof 2006. Due to the limited supply, CDC is now recommending thatproviders immunize only adolescents at high school entry who havenot previously received MCV4 as well as college freshman living indormitories.
CMS proposes new Part D marketing guidelines
May 30th 2006Remember the long list of do's and don'ts CMS came up with latelast year related to how the Medicare Part D plans are to bemarketed? CMS has proposed new guidelines for the 2007 contractyear and has given only one week's time for the public to comment.
New indication granted for Remicade
May 30th 2006Children with active Crohn's disease will now have a new treatmentoption as the FDA has given the regulatory nod to infliximab(Remicade, Centocor) for the treatment of the disease. Themonoclonal antibody works to reduce the inflammation of the bowelassociated with Crohn's by blocking the action of tumor necrosisfactor-alpha and inducing remission of the condition.
Study says: Rx purchases at drugstores drop
May 22nd 2006Fifty-eight percent of adults have visited a drugstore in the past30 days to make a prescription purchase, a decrease from 62% in2004 and 64% in 2000, according to the results of a recent Vertisstudy. Vertis is a Baltimore, Md.-based provider of targetedadvertising, media, and marketing services.
E-prescribing pays, says RxHub study
May 22nd 2006Electronic prescribing that includes patient-specific formularyinformation could cut a payer's drug spend by 8% to 15% anddrug-spend inflation could be reduced by as much as 1% per year,according to an analysis commissioned by RxHub. An e-prescribingnetwork, RxHub processed more than 26 million requests forpatient-specific eligibility, benefit, and formulary informationlast year and is on track to top 60 million patient events thisyear.